Gut microbiota-derived metabolites: Potential targets for cardiorenal syndrome
Pharmacological Research · 2025-04 · 214 · 107672
DOI: 10.1016/j.phrs.2025.107672 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2025-04. Verfasst von Yuchen Lai und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China. Hauptthemen laut MEDLINE: Cardio-Renal Syndrome, Gastrointestinal Microbiome. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The characteristic of cardiorenal syndrome (CRS) is simultaneous damage to both the heart and kidneys. CRS has caused a heavy burden of mortality and incidence rates worldwide. The regulation of host microbiota metabolism that triggers heart and kidney damage is an emerging research field that promotes a new perspective on cardiovascular risk. We summarize current studies from bench to bedside of gut microbiota-derived metabolites to better understand CRS in the context of gut microbiota-derived metabolites. We focused on the involvement of gut microbiota-derived metabolites in the pathophysiology of CRS, including lipid and cholesterol metabolism disorders, coagulation abnormalities and platelet aggregation, oxidative stress, endothelial dysfunction, inflammation, mitochondrial damage and energy metabolism disorders, vascular calcification and renal fibrosis, as well as emerging therapeutic approaches targeting CRS metabolism in gut microbiota-derived metabolites which provides an innovative treatment approach for CRS to improve patient prognosis and overall quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China.
- The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, State Key Laboratory of Vascular Homeostasis and Remodeling, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides,…
- Department of Blood Purification, General Hospital of Central Theater Command(Hankou Campus), No.68, Huangpu Avenue, Wuhan, 430010, China.
- Department of Cardiology, General Hospital of Central Theater Command, No.627, Wuluo Road, Wuhan 430070, China.
- Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases, Advanced Innovation Center for Human Brain Protection, Beijing Institute of Brain Disorders, The Capital Medical University, B…
- Department of Cardiology, General Hospital of Central Theater Command, No.627, Wuluo Road, Wuhan 430070, China. Electronic address: huangwei0521@126.com.
Zitieren
APA
Lai, Y., Zhu, Y., Zhang, X., Ding, S., Wang, F., Hao, J., Wang, Z., Shi, C., Xu, Y., Zheng, L., & Huang, W. (2025). Gut microbiota-derived metabolites: Potential targets for cardiorenal syndrome. Pharmacological Research, 214, 107672. https://doi.org/10.1016/j.phrs.2025.107672
Vancouver
Lai Y, Zhu Y, Zhang X, Ding S, Wang F, Hao J, et al. Gut microbiota-derived metabolites: Potential targets for cardiorenal syndrome. Pharmacological Research. 2025;214:107672. doi:10.1016/j.phrs.2025.107672
BibTeX
@article{Lai2025,
author = {Lai, Yuchen and Zhu, Yujie and Zhang, Xihui and Ding, Shifang and Wang, Fang and Hao, Jincen and Wang, Zhaomeng and Shi, Congqi and Xu, Yongjin and Zheng, Lemin and Huang, Wei},
title = {Gut microbiota-derived metabolites: Potential targets for cardiorenal syndrome},
journal = {Pharmacological Research},
year = {2025},
volume = {214},
pages = {107672},
doi = {10.1016/j.phrs.2025.107672}
}
EUVIMED